<s>[INST] The next text is a question of a member of the European parliament:"In 2011, the European Medicines Agency (EMA) launched a Geriatric Medicines Strategy. This is one of the means which the EMA has its disposal for taking account of the specific needs and characteristics of older people in the development and assessment of new medicines. The strategy is particularly concerned with:      —  ensuring that the medicines used by older people are of high quality and are tested on the older population before being authorised;      —  improving the availability of information for older people on the use of medicines.    A Geriatric Expert Group was set up in 2012 to provide advice and support for the strategy, as part of the Committee for Medicinal Products for Human Use (CHMP).  Can the Commission provide information about:      1.  the situation with regard to the implementation of this strategy and the extent to which it has been applied to newly registered medicines?      2.  the specific number of requests for advice from the CHMP to the Geriatric Expert Group?      3.  whether there has been any improvement in participation by older people in clinical trials of new medicines?"
Analyze carefully the text and assign it to the most relevant policy area among those listed below. Do not explain your answer and return only a number.
Policy area numbers: 1 = Macroeconomics
2 = Civil Rights, Minority Issues and Civil Liberties
3 = Health
4 = Agriculture and Fisheries
5 = Labour, employment and pensions
6 = Education
7 = Environment
8 = Energy
9 = Immigration
10 = Transportation
12 = Law and Crime
13 = Social welfare
14 = Regional and Urban issues and Planning
15 = Banking, finance and domestic commerce issues
16 = Defence
17 = Space, science, technology, and communications issues
18 = Foreign trade
19 = International affairs and foreign aid
20 = Governance and government
21 = Public Lands, Water Management and Territorial Issues
23 = Culture and media
[/INST]. Answer = [3]. </s>
In 2011, the European Medicines Agency (EMA) launched a Geriatric Medicines Strategy. This is one of the means which the EMA has its disposal for taking account of the specific needs and characteristics of older people in the development and assessment of new medicines. The strategy is particularly concerned with:      —  ensuring that the medicines used by older people are of high quality and are tested on the older population before being authorised;      —  improving the availability of information for older people on the use of medicines.    A Geriatric Expert Group was set up in 2012 to provide advice and support for the strategy, as part of the Committee for Medicinal Products for Human Use (CHMP).  Can the Commission provide information about:      1.  the situation with regard to the implementation of this strategy and the extent to which it has been applied to newly registered medicines?      2.  the specific number of requests for advice from the CHMP to the Geriatric Expert Group?      3.  whether there has been any improvement in participation by older people in clinical trials of new medicines?